GRCE Relative Valuation
GRCE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, GRCE is overvalued; if below, it's undervalued.
Historical Valuation
Grace Therapeutics, Inc (GRCE) is now in the Fair zone, suggesting that its current forward PS ratio of 25.21 is considered Fairly compared with the five-year average of -3.08. The fair price of Grace Therapeutics, Inc (GRCE) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：3.73
Fair
-3.23
PE
1Y
3Y
5Y
-2.07
EV/EBITDA
Grace Therapeutics, Inc. (GRCE) has a current EV/EBITDA of -2.07. The 5-year average EV/EBITDA is -1.30. The thresholds are as follows: Strongly Undervalued below -1.92, Undervalued between -1.92 and -1.61, Fairly Valued between -1.00 and -1.61, Overvalued between -1.00 and -0.69, and Strongly Overvalued above -0.69. The current Forward EV/EBITDA of -2.07 falls within the Strongly Undervalued range.
-1.96
EV/EBIT
Grace Therapeutics, Inc. (GRCE) has a current EV/EBIT of -1.96. The 5-year average EV/EBIT is -1.39. The thresholds are as follows: Strongly Undervalued below -2.02, Undervalued between -2.02 and -1.70, Fairly Valued between -1.07 and -1.70, Overvalued between -1.07 and -0.76, and Strongly Overvalued above -0.76. The current Forward EV/EBIT of -1.96 falls within the Undervalued range.
25.21
PS
Grace Therapeutics, Inc. (GRCE) has a current PS of 25.21. The 5-year average PS is 13.95. The thresholds are as follows: Strongly Undervalued below -23.64, Undervalued between -23.64 and -4.85, Fairly Valued between 32.74 and -4.85, Overvalued between 32.74 and 51.54, and Strongly Overvalued above 51.54. The current Forward PS of 25.21 falls within the Historic Trend Line -Fairly Valued range.
-2.67
P/OCF
Grace Therapeutics, Inc. (GRCE) has a current P/OCF of -2.67. The 5-year average P/OCF is -2.23. The thresholds are as follows: Strongly Undervalued below -2.75, Undervalued between -2.75 and -2.49, Fairly Valued between -1.97 and -2.49, Overvalued between -1.97 and -1.71, and Strongly Overvalued above -1.71. The current Forward P/OCF of -2.67 falls within the Undervalued range.
-2.67
P/FCF
Grace Therapeutics, Inc. (GRCE) has a current P/FCF of -2.67. The 5-year average P/FCF is -2.23. The thresholds are as follows: Strongly Undervalued below -2.75, Undervalued between -2.75 and -2.49, Fairly Valued between -1.97 and -2.49, Overvalued between -1.97 and -1.71, and Strongly Overvalued above -1.71. The current Forward P/FCF of -2.67 falls within the Undervalued range.
Grace Therapeutics, Inc (GRCE) has a current Price-to-Book (P/B) ratio of 0.82. Compared to its 3-year average P/B ratio of 0.63 , the current P/B ratio is approximately 30.74% higher. Relative to its 5-year average P/B ratio of 0.63, the current P/B ratio is about 30.74% higher. Grace Therapeutics, Inc (GRCE) has a Forward Free Cash Flow (FCF) yield of approximately -21.21%. Compared to its 3-year average FCF yield of -33.55%, the current FCF yield is approximately -36.77% lower. Relative to its 5-year average FCF yield of -33.55% , the current FCF yield is about -36.77% lower.
0.82
P/B
Median3y
0.63
Median5y
0.63
-21.21
FCF Yield
Median3y
-33.55
Median5y
-33.55
Competitors Valuation Multiple
The average P/S ratio for GRCE's competitors is 1318.07, providing a benchmark for relative valuation. Grace Therapeutics, Inc Corp (GRCE) exhibits a P/S ratio of 25.21, which is -98.09% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of GRCE increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of GRCE in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is Grace Therapeutics, Inc (GRCE) currently overvalued or undervalued?
Grace Therapeutics, Inc (GRCE) is now in the Fair zone, suggesting that its current forward PS ratio of 25.21 is considered Fairly compared with the five-year average of -3.08. The fair price of Grace Therapeutics, Inc (GRCE) is between to according to relative valuation methord.
What is Grace Therapeutics, Inc (GRCE) fair value?
GRCE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Grace Therapeutics, Inc (GRCE) is between to according to relative valuation methord.
How does GRCE's valuation metrics compare to the industry average?
The average P/S ratio for GRCE's competitors is 1318.07, providing a benchmark for relative valuation. Grace Therapeutics, Inc Corp (GRCE) exhibits a P/S ratio of 25.21, which is -98.09% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Grace Therapeutics, Inc (GRCE) as of Jan 08 2026?
As of Jan 08 2026, Grace Therapeutics, Inc (GRCE) has a P/B ratio of 0.82. This indicates that the market values GRCE at 0.82 times its book value.
What is the current FCF Yield for Grace Therapeutics, Inc (GRCE) as of Jan 08 2026?
As of Jan 08 2026, Grace Therapeutics, Inc (GRCE) has a FCF Yield of -21.21%. This means that for every dollar of Grace Therapeutics, Inc’s market capitalization, the company generates -21.21 cents in free cash flow.
What is the current Forward P/E ratio for Grace Therapeutics, Inc (GRCE) as of Jan 08 2026?
As of Jan 08 2026, Grace Therapeutics, Inc (GRCE) has a Forward P/E ratio of -3.23. This means the market is willing to pay $-3.23 for every dollar of Grace Therapeutics, Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Grace Therapeutics, Inc (GRCE) as of Jan 08 2026?
As of Jan 08 2026, Grace Therapeutics, Inc (GRCE) has a Forward P/S ratio of 25.21. This means the market is valuing GRCE at $25.21 for every dollar of expected revenue over the next 12 months.